Coya Therapeutics, Inc. financial data

Symbol
COYA on Nasdaq
Industry
Pharmaceutical Preparations
Location
12645 Memorial Dr., Suite F1 #305, Houston, TX
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 868 %
Debt-to-equity 15.1 %
Return On Equity -35.6 % +89.2%
Return On Assets -31 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 15.2M shares +53%
Common Stock, Shares, Outstanding 15.2M shares +53%
Entity Public Float 36.4M USD
Common Stock, Value, Issued 1.52K USD +52.9%
Weighted Average Number of Shares Outstanding, Basic 14.9M shares +49.9%
Weighted Average Number of Shares Outstanding, Diluted 14.9M shares +49.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 3.43M USD
General and Administrative Expense 8.87M USD +57.7%
Operating Income (Loss) -10.5M USD +3.25%
Net Income (Loss) Attributable to Parent -10.1M USD +22.1%
Earnings Per Share, Basic -0.74 USD/shares +77.8%
Earnings Per Share, Diluted -0.74 USD/shares +77.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 36.6M USD +179%
Assets, Current 39.9M USD +177%
Property, Plant and Equipment, Net 52.3K USD -34.4%
Assets 39.9M USD +176%
Accounts Payable, Current 1.88M USD +693%
Accrued Liabilities, Current 1M USD +2%
Liabilities, Current 3.83M USD +213%
Liabilities 4.68M USD +283%
Retained Earnings (Accumulated Deficit) -33.8M USD -42.6%
Stockholders' Equity Attributable to Parent 35.3M USD +166%
Liabilities and Equity 39.9M USD +176%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 2.15M USD
Net Cash Provided by (Used in) Financing Activities 1.24M USD -91.3%
Net Cash Provided by (Used in) Investing Activities -25K USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 15.2M shares +53%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Deferred Tax Assets, Valuation Allowance 5.63M USD +78.9%
Depreciation 27.4K USD -17%
Property, Plant and Equipment, Gross 137K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 439K USD -27.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 69.1M USD +86.9%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 1.6M USD +212%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%